We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App





Horiba Medical Exhibits New Generation of Automated Hematology Analyzers at MEDLAB Middle East 2021

By LabMedica International staff writers
Posted on 23 Jun 2021
Print article
Image: Horiba Medical Exhibits New Generation of Automated Hematology Analyzers at MEDLAB Middle East 2021 (Photo courtesy of Horiba Medical)
Image: Horiba Medical Exhibits New Generation of Automated Hematology Analyzers at MEDLAB Middle East 2021 (Photo courtesy of Horiba Medical)
Horiba Medical (Kyoto, Japan) presented its high-end hematology solutions alongside different configurations of laboratory organization as well as its comprehensive range of hemostasis and clinical chemistry instruments at MEDLAB Middle East 2021.

On display at the event were the Yumizen H2500, Yumizen SPS and Yumizen P8000 - the new generation of Horiba automated hematology analyzers that answers customers’ expectations of solid and reliable diagnostic technology as well as rapid and consistent results. Some of their features include a real throughput of 120 samples per hour for CBC-DIFF, NRBC included, sampling volume of 110μl (CBC, DIFF, BF) and 75μL (Slide), only six reagents, automatic 360° rotative sample mixing for perfect homogeneity, two PLT technologies - Impedance & Optical extinction – and three WBC counts in CBC and differential modes. All the instruments are compatible with the HELO Solution (HORIBA Evolutive Laboratory Organization).

Horiba also showcased its Yumizen H500 and H550 analyzers that have been designed to deliver a rapid and comprehensive hematology report with a throughput of 60 tests/hour, 40 tubes autonomy with continuous loading, urgent manual mode; and for running samples through multi analysis modes and sampling. Based on color codes, minimum operation and quality flagging messages, the ergonomics of the new Yumizen H500 and H550 are perfectly dedicated to users of small size laboratories such as emergency rooms or physician office labs. With its menu of extensive parameters and enhanced clinical performances the new Yumizen H500 and H550 analyzers are capable of meeting the demands of a variety of clinical lab environments and clinical settings: routine hematology, satellites labs, oncology care, blood banks.

In addition, Horiba highlighted the Microsemi LC-667G hematology analyzer featuring the exclusive concept of simultaneous blood analysis + CRP measurement, along with data management. It is the first hematology analyzer to offer malaria screening flag combined with CBC count. The Malaria screening flag with high sensitivity alerts the physician about suspicion of malaria infection and is available in CBC or CBC+CRP routine use without any specific reagent or dedicated mode. The added value is part of a complete solution of using the MicrosEmi CRP as an infectious differentiator.

Related Links:
Horiba Medical

Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
MTHFR Mutation Test
REALQUALITY THROMBO MTHFR
New
Urine Control
MassCheck Amino Acid Analysis Urine Controls

Print article

Channels

Molecular Diagnostics

view channel
Image: Low levels of a protein that signals placental development could alert physicians to the need for enhanced monitoring (Photo courtesy of Shutterstock)

Blood Test Could Identify Expectant Mothers at Risk of Preterm Delivery

Early preterm birth, defined as delivery before 34 weeks of gestation, carries significant risks for adverse health outcomes. However, there is no universal screening strategy available, which limits the... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.